---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-016698"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-06-09T23:59:59+00:00"
generated_at: "2026-06-25T03:16:02.823098+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arcutis Biotherapeutics reports positive Phase 3 STRATUM results for roflumilast foam in seborrheic dermatitis

## Summary
- 80.1% of patients on roflumilast foam achieved IGA success at week 8 vs 59.2% vehicle (p<0.0001)
- 50.7% achieved an IGA score of clear at week 8 compared to 28.2% with vehicle (p<0.0001)
- Treatment was well-tolerated; discontinuation due to adverse events was 0.7% for roflumilast vs 2.0% for vehicle
- NDA submission to FDA for roflumilast foam in seborrheic dermatitis anticipated in first half of 2023

## SEC filing metadata
- accession: 0001628280-22-016698
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828022016698/0001628280-22-016698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828022016698/arqt-20220606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-016698
- JSON: https://secwatch.observer/filing/0001628280-22-016698.json
- Plain text: https://secwatch.observer/filing/0001628280-22-016698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.